Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08ZQI
|
|||
| Former ID |
DIB000029
|
|||
| Drug Name |
FPA-008
|
|||
| Indication | Autoimmune diabetes [ICD-11: 5A10] | Phase 1/2 | [1] | |
| Pigmented villonodular synovitis [ICD-11: FA27.1; ICD-10: M12.2] | Phase 1 | [2] | ||
| Tenosynovial giant cell tumour [ICD-11: 2F7B; ICD-10: D48.0] | Phase 1 | [2] | ||
| Company |
Five prime therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Colony stimulating factor-1 receptor (CSF-1R) | Target Info | Modulator | [3] |
| Macrophage colony-stimulating factor 1 receptor (CSF1R) | Target Info | . | [2] | |
| KEGG Pathway | MAPK signaling pathway | |||
| Ras signaling pathway | ||||
| Rap1 signaling pathway | ||||
| Cytokine-cytokine receptor interaction | ||||
| Viral protein interaction with cytokine and cytokine receptor | ||||
| PI3K-Akt signaling pathway | ||||
| Osteoclast differentiation | ||||
| Hematopoietic cell lineage | ||||
| Pathways in cancer | ||||
| Transcriptional misregulation in cancer | ||||
| Acute myeloid leukemia | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039179) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Company report (Five Prime Therapeutics) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.